Learn About Heterozygous Familial Hypercholesterolemia (HeFH)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Mika Hori practices in Nagoya, Japan. Hori is rated as an Elite expert by MediFind in the treatment of Heterozygous Familial Hypercholesterolemia (HeFH). Their top areas of expertise are Heterozygous Familial Hypercholesterolemia (HeFH), Familial Hypercholesterolemia, High Cholesterol, Defective Apolipoprotein B-100, and Pancreaticoduodenectomy.
Mariko Shiba-Harada practices in Osaka, Japan. Ms. Shiba-Harada is rated as an Elite expert by MediFind in the treatment of Heterozygous Familial Hypercholesterolemia (HeFH). Her top areas of expertise are Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Familial Hypercholesterolemia, and Homozygous Familial Hypercholesterolemia (HoFH).
Frederick Raal practices in Johannesburg, South Africa. Mr. Raal is rated as an Elite expert by MediFind in the treatment of Heterozygous Familial Hypercholesterolemia (HeFH). His top areas of expertise are Homozygous Familial Hypercholesterolemia (HoFH), Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, and Familial Hypercholesterolemia.
Summary: This study is designed to learn if enlicitide decanoate is safe and effective to treat children and adolescents with heterozygous familial hypercholesterolemia (HeFH) and high amounts of low-density lipoprotein cholesterol (LDL-C) in the blood. The goals of this study are to learn about the safety of enlicitide and if children tolerate it, what happens to enlicitide in a child's body over time, an...
Summary: The Investigators will test the hypothesis that 2-HOBA will reduce modification of HDL and LDL and improve HDL function in humans with heterozygous FH. The Investigators plan to first study subjects with Familial Hypercholesterolemia (FH), treating them with 750 mg of 2-HOBA or placebo every 8 hours for 6 weeks.